Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 February 2008, Vol. 111, No. 3, pp. 1248-1256.
Prepublished online as a Blood First Edition Paper on October 31, 2007; DOI 10.1182/blood-2007-08-105544.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Videos
Right arrow All Versions of this Article:
blood-2007-08-105544v1
111/3/1248    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blue, R.
Right arrow Articles by Coller, B. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blue, R.
Right arrow Articles by Coller, B. S.
Related Collections
Right arrow Hemostasis, Thrombosis, and Vascular Biology
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY

Application of high-throughput screening to identify a novel {alpha}IIb-specific small- molecule inhibitor of {alpha}IIbβ3-mediated platelet interaction with fibrinogen

Robert Blue1, Marta Murcia2, Charles Karan3, Markéta Jirousková1, and Barry S. Coller1

1 Laboratory of Blood and Vascular Biology, The Rockefeller University, New York, NY; 2 Department of Physiology and Biophysics, Weill Cornell Medical College, New York, NY; and 3 High Throughput Screening Resource Center, The Rockefeller University, New York, NY

Small-molecule {alpha}IIbβ3 antagonists competitively block ligand binding by spanning between the D224 in {alpha}IIb and the MIDAS metal ion in β3. They variably induce conformational changes in the receptor, which may have undesirable consequences. To identify {alpha}IIbβ3 antagonists with novel structures, we tested 33 264 small molecules for their ability to inhibit the adhesion of washed platelets to immobilized fibrinogen at 16 µM. A total of 102 compounds demonstrated 50% or more inhibition, and one of these (compound 1, 265 g/mol) inhibited ADP-induced platelet aggregation (IC50: 13± 5 µM), the binding of soluble fibrinogen to platelets induced by mAb AP5, and the binding of soluble fibrinogen and a cyclic RGD peptide to purified {alpha}IIbβ3. Compound 1 did not affect the function of GPIb, {alpha}2β1, or the other β3 family receptor {alpha}Vβ3. Molecular docking simulations suggest that compound 1 interacts with {alpha}IIb but not β3. Compound 1 induced partial exposure of an {alpha}IIb ligand-induced binding site (LIBS), but did not induce exposure of 2 β3 LIBS. Transient exposure of purified {alpha}IIbβ3 to eptifibatide, but not compound 1, enhanced fibrinogen binding ("priming"). Compound 1 provides a prototype for small molecule selective inhibition of {alpha}IIbβ3, without receptor priming, via targeting {alpha}IIb.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
Sponsor: Genentech BioOncology and and Biogen Idec
Blood Online is supported in part by
Genentech BioOncology and Biogen Idec
  Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020